Moy Beverly, Goss Paul E
Massachusetts General Hospital Cancer Center, Gillette Center for Women's Cancers, Lawrence House, LRH 304, Boston, MA 02114, USA.
Oncologist. 2007 Jul;12(7):756-65. doi: 10.1634/theoncologist.12-7-756.
Lapatinib is an oral receptor tyrosine kinase inhibitor, inhibiting both the ErbB-1 and ErbB-2 receptors. Lapatinib has been shown to have activity in ErbB-2-overexpressing breast cancer in several phase II and III clinical trials. Specifically, lapatinib is effective in patients with metastatic breast cancer, with inflammatory breast cancer, and possibly, with brain metastases. An ongoing clinical trial and another anticipated clinical trial will investigate lapatinib as adjuvant treatment in early-stage disease. Lapatinib has specific toxicities, the most common being diarrhea and rash. Cardiac toxicity is rarely seen with lapatinib. This paper reviews lapatinib-associated toxicities and provides practical management recommendations based on available data.
拉帕替尼是一种口服受体酪氨酸激酶抑制剂，可抑制表皮生长因子受体-1（ErbB-1）和表皮生长因子受体-2（ErbB-2）。在多项II期和III期临床试验中，拉帕替尼已显示出对ErbB-2过表达的乳腺癌具有活性。具体而言，拉帕替尼对转移性乳腺癌、炎性乳腺癌患者有效，可能对脑转移患者也有效。一项正在进行的临床试验和另一项预期的临床试验将研究拉帕替尼作为早期疾病的辅助治疗。拉帕替尼有特定的毒性，最常见的是腹泻和皮疹。拉帕替尼很少出现心脏毒性。本文综述了拉帕替尼相关的毒性，并根据现有数据提供了实际的管理建议。
